Infection control basis for recommending one-time use of sterile syringes and aseptic procedures for injection drug users

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue SUPPL., 1998, Pages

  Gershon, Robyn R M ^a,b  

^a The Johns Hopkins University   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Blood borne infections; HIV; Infection control; Infections; Injection drug user; Sterility; Syringes

Indexed keywords

ARTICLE; DISPOSABLE EQUIPMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYGIENE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INSTRUMENT STERILIZATION; INTRAVENOUS DRUG ABUSE; MEDICAL INSTRUMENTATION; NEEDLE; PRIORITY JOURNAL; SYRINGE;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0032125417     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802001-00005     Document Type: Article

References (58)

1. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996:86;642-4.
2. CDC. AIDS associated with injecting-drug use - United States, 1995. MMWR Morb Mortal Wkly Rep 1996;45:392-8.
3. Alter M. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
4. Garfein RS, Vlahov D, Galai N, et al. Viral Infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.
5. Vlahov D, Khabbaz RF, Cohn S, et al. Incidence and risk factors for human T-lymphoctropic virus type II (HTLV-II) seroconversion among injecting drug users in Baltimore, Maryland. J Acquir Immune Defic Syndr 1995;9:89-96.
6. Vlahov D, Khabbaz RF, Cohn S, et al. Incidence and risk factors for human T-lymphoctropic virus type II (HTLV-II) seroconversion among injecting drug users in Baltimore, Maryland. J Acquir Immune Defic Syndr 1995;9:89-96.
7. Heimer R, Khoshnood K, Jariwalafreeman B, et al. Hepatitis in used syringes - the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens. J Infect Dis 1996;173: 997-1000.
8. Gonzalez MH, Garst J, Nourbash P, et al. Abscesses of the upper extremity from drug abuse by injection. J Hand Surg Am 1993; 18:868-70.
9. Schnall SB, Holtom PD, Lilley JC. Abscesses secondary to parenteral abuse of drugs: a study of demographic and bacteriological characteristics. J Bone Joint Surg Am 1994;76:1526-30.
10. Hemingway DM, Balfour AE, McCartney AC, Leiberman DP. Streptococcus milleri and complex groin abscesses in intravenous drug abusers. Scott Med J 1992;37:116-7.
11. Elston HR, Wang M, Loo LK. Arm abscesses caused by Clostridium botulinum. J Clin Microbiol 1991;29:2678-9.
12. Centers for Disease Control. Wound botulism - California, 1995. MMWR Morb Mortal Wkly Rep 1995;44:889-92.
13. Watanakunakorn C, Burkert T. Infective endocarditis at a large community teaching hospital, 1980-1990: a review of 210 episodes [review]. Medicine (Baltimore) 1993;72:90-102.
14. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users: prognostic features in 102 episodes. Ann Intern Med 1992; 117:560-6.
15. Graves MK, Soto L. Left-sided endocarditis in patenteral drug abusers: recent experience at a large community hospital. South Med J 1992;85:378-80.
16. Van Winter JT, Nielsen SN, Ogburn PL Jr. Epidural abscess associated with intravenous drug abuse in a pregnant patient. Mayo Clin Proc 1991;66:1036-9.
17. U.S. Public Health Service. HIV prevention bulletin: medical advice for persons who inject illicit drugs. Atlanta: Centers for Disease Control and Prevention, May 9, 1997.
18. Favero MS, Bond WW. Sterilization, disinfection and antisepsis in the hospital. In: Manual of clinical microbiology. Washington, DC: American Society for Microbiology, 1991:183-200.
19. United States Food and Drug Administration. Compliance policy guide: re-use of medical disposable devices. Washington, DC: Food and Drug Administration. September 24, 1987.
20. Haley RW. CDC guidelines on infection control. Infect Control 1981;2:1-2.
21. Garner JS, Favero MS, Centers for Disease Control. Guidelines for handwashing and hospital environmental control. Infect Control 1985;7:231-43.
22. Centers for Disease Control. Improper infection-control practices during employee vaccination programs-District of Columbia and Pennsylvania, 1993. MMWR Morb Mortal Wkly Rep 1993;42:969-71.
23. Watters JK. Historical perspective on the use of bleach in HIV/ AIDS prevention. J Acquir Immune Defic Syndr 1994;7:743-746.
24. Vlahov D, Astemborski J, Solomon L, Nelson K. Field effectiveness of needle disinfection among injecting drug users. J Acquir Immune Defic Syndr 1994;7:760-6.
25. Shapshak P, McCoy CB, Rivers JE, et al. Inactivation of human immunodeficiency virus at short intervals using undiluted bleach. J Acquir Immune Defic Syndr 1993;6:218-9.
26. Gleghorn AA, Doherty MC, Vlahov D, et al. Inadequate bleach contact times during syringe cleaning among injecting drug users. J Acquir Immune Defic Syndr 1994;7:768-73.
27. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press, 1995.
28. Koenig RE, Gautier T. Unusual intrafamilial transmission of human immunodeficiency virus. Lancet 1986;2:627.
29. Chant D, Lowe D, Rubin G, et al. Patient to patient transmission of HIV in private surgical consulting rooms. Lancet 1993;342: 1548-9.
30. Centers for Disease Control. Patient exposures to HIV during nuclear medicine procedures. MMWR Morb Mortal Wkly Rep 1992;41:575-8.
31. Alter MJ, Ahtone J, Maynard JE. Hepatitis B transmission associated with a multiple-dose vial in a unit. Ann Intern Med 1983; 99:330-3.
32. Froggatt JW, Dwyer DM, Stephens MA. Hospital outbreak of hepatitis B in patients undergoing electroconvulsive therapy. Program and abstracts of the Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1991. Washington, DC: American Society of Microbiology, 1991.
33. Hlady W, Hopkins RS, Ogilby T, et al. Patient to patient transmission of hepatitis B in a dermatology practice. Presented at the Fifth National Forum on AIDS, Hepatitis, and Other Bloodborne Diseases, Atlanta, March 1992.
34. Pokrovsky VV, Eramova EU. Nosocomial outbreak of HIV infection in Elista, USSR. Abstract from IV International Conference on AIDS [Abstract W.A.0.5]. Montreal, Canada, June 1989.
35. Hersh BS, Popovici F, Jezek Z, et al. Factors for HIV infection among abandoned Romanian children. AIDS 1993;7:1617-24.
36. Hersh BS, Popovici F, Apetrei RC, et al. Acquired immunodeficiency syndrome in Romania. Lancet 1991;338:645-49.
37. Berkley S. Parenteral transmission of HIV in Africa. AIDS 1991;5(Suppl 1):S87-S92.
38. Mintz M, Boland M, O Hara M, et al. Pediatric HIV Infection in Elista, Russia: Interventional Strategies [letter]. Am J Public Health 1995:85:586-8.
39. Gremillion DH, Mursch SB, Lerner CJ. Injection site abscesses caused by Mycobacterium chelonei. Infect Control 1983;4:25-28.
40. Bernier RH, Frank JA, Nolan TF. Abscesses complicating DPT vaccination. Am J Dis Child 1981;135:826-8.
41. Plott RT, Wagner RF, Tyring SK. Iatrogenic contamination of multidose vials in simulated use: a reassessment of current patient injection technique. Arch Dermatol 1990;136:1441-4.
42. Druce JD, Locarnini SA, Birch, CJ. Isolation of HIV-1 from experimentally contaminated multidose local anesthetic vials. Med J Aust 1995;162:513-5.
43. Haverkos HW, Lange WR. Serious infections other than human immunodeficiency virus among intravenous drug users. J Infect Dis 1990;161:894-902.
44. Herb F, Watters JK, Case P, et al. Endocarditis, subcutaneous abscesses, and other bacterial infections in intravenous drug users and their association with skin cleaning at drug injection sites [abstract Th.D.O.4]. Presented at the Fifth International Conference on AIDS. Montreal, Canada, June 8, 1989.
45. Vlahov D, Sullivan M, Astemborski J, Nelson KE. Bacterial infections and skin cleaning prior to injection among intravenous drug users. Public Health Rep 1992;107:595-8.
46. Position statement: insulin administration. Diabetes Care 1993;16(Suppl 2):31-4.
47. Borders LM, Bingham PR, Riddle MC. Traditional insulin-use practices and the incidence of bacterial contamination and infection. Diabetes Care 1984;7:121-7.
48. Hodge R, Krongaard L, Sande MA, Kasier DL. Multiple use of disposable insulin syringe-needle units. JAMA 1980;244:266-7.
49. Koester SK, Hoffer L. Indirect sharing: additional HIV risks associated with drug injection. AIDS Public Policy J 1994;9:100-5.
50. McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral Transmission of HIV Among Injection Drug Users: Assessing the Frequency of Multiperson Use of Needles, Syringes, Cookers, Cotton, and Water. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S25-9.
51. Vlahov D. Backloading and HIV infection among injection drug users. Int J Drug Policy 1996;7:52-7.
52. Jose B, Friedman SR, Neaigus A, et al. Syringe-mediated drug-sharing (backloading): a new risk factor for HIV among injecting drug users. AIDS 1993;7:1653-60.
53. Grand JP, Friedman SR, Stern LS, et al. Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of bloodborne pathogens. Soc Sci Med 1996;42:691-703.
54. Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/ AIDS and other bloodborne diseases among injection drug users: A national survey on the regulation of syringes and needles. JAMA 1997;277:53-62.
55. Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med 1985;103:755-9.
56. Vlahov D. Deregulation of the sale and possession of syringes for HIV prevention among injection drag users. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:71-2.
57. Lundberg GD. New winds blowing for American drug policies [editorial]. JAMA 1997;278:946-7.
58. Holtgrave DR, Pinkerton SD, Jones TS, et al. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S133-8.